BioVie Inc.
NASDAQBIVI heads into its most critical near-term catalyst — topline Phase 2 data for bezisterim in Parkinson's disease — having gained 12% on the week and 20% over the past month, closing at $1.68. The stock's move is being driven by clinical anticipation rather than short mechanics. Short interest has fallen sharply — down 18% on the week and nearly 19% over the past month to 1.7% of…
Snapshot as of 8 May 2026
BIVI heads into its most critical near-term catalyst — topline Phase 2 data for bezisterim in Parkinson's disease — having gained 12% on the week and 20% over the past month, closing at $1.68. The stock's move is being…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIVI — free to start on ORTEX.
Sign up for free →Open BIVI on ORTEX